Quantcast
Last updated on April 16, 2014 at 12:31 EDT

Latest National Institute of Allergy and Infectious Diseases Stories

2013-05-17 16:24:47

SAN DIEGO, May 17, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCBB: SRNE; or STI) announced today that its Fast-Track Advanced Technology Small Business Technology Transfer Research (STTR) grant (#1R42AI098182-02) from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), supporting the development of novel human antibody therapeutics to combat Staphylococcus aureus (S. aureus or Staph) infections, including...

2013-05-15 08:29:48

PRINCETON, N.J., May 15, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease. The program has...

2013-05-01 08:30:52

Soligenix to Expand Biodefense and Infectious Disease Product Pipeline PRINCETON, N.J. and GERMANTOWN, Md., May 1, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today it will jointly develop a treatment for Melioidosis through a worldwide exclusive collaboration with Intrexon, a synthetic...

2013-04-19 17:59:57

Baylor College of Medicine researchers will lead a three-year, $4.2 million study funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to determine whether drugs called beta blockers can ease airway narrowing in patients with asthma and examine potential mechanisms. Researchers from Duke University in Durham, North Carolina, and Washington University in St. Louis, Missouri, also will participate. "Previously, beta...

2013-04-18 19:23:44

Interferon and ribavirin inhibit virus replication in cell culture, NIH study finds National Institutes of Health (NIH) scientists studying an emerging coronavirus have found that a combination of two licensed antiviral drugs, ribavirin and interferon-alpha 2b, can stop the virus from replicating in laboratory-grown cells. These results suggest that the drug combination could be used to treat patients infected with the new coronavirus, but more research is needed to confirm this...

2013-04-16 08:28:30

Presentation on April 18, 2013 PRINCETON, N.J., April 16, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products for serious inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that its Chief Scientific Officer, Robert N. Brey, PhD, will give a presentation on the stockpiling of biodefense vaccines - technology...

2013-04-04 11:48:58

National Institutes of Health (NIH) researchers have developed a model of infection in rhesus macaques that will help scientists around the world better understand how an emerging coronavirus, first identified in September 2012, affects people. The virus has so far infected at least 17 people in the Middle East and Europe, killing 11 of them. The NIH team established the nonhuman primate model in December 2012 and is using it to study how the virus causes disease and to evaluate potential...

2013-03-19 08:26:31

Research Conducted under $9.4 Million NIAID Cooperative Grant PRINCETON, N.J., March 19, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today key progress in the development of ThermoVax(TM), its proprietary vaccine thermostabilization technology. Several complementary preclinical studies have indicated the potential for high temperature stability for a minimum of six months and increased potency of...

First-Ever HIV Cure Found For Mississippi Baby
2013-03-04 08:16:15

Lawrence LeBlond for redOrbit.com - Your Universe Online AIDS research has come a long way since the disease was first clinically discovered in 1981 and officially named by the US Centers for Disease Control and Prevention (CDC) in 1982. And although many hurdles had been overcome in the prevention and treatment of the world´s deadliest sexually-transmitted infection (STI) over the past thirty years, no real cure had ever been found. That is until today. Unveiling their landmark...

2013-02-26 12:28:04

NIAID Initiates Clinical Trial of STEBVax, a Staphylococcal Enterotoxin B Vaccine GAITHERSBURG, Md., Feb. 26, 2013 /PRNewswire/ -- Integrated BioTherapeutics (IBT) announces the initiation of a Phase 1 clinical trial testing the safety and immunogenicity of its staphylococcal enterotoxin B vaccine "STEBVAX" in healthy adults. This trial, marking the first time a superantigen vaccine has been administered to humans, is designed to enroll 28 individuals. STEBVax is a proprietary,...